clinicalRSVP, a participant registry that prevents research volunteers from enrolling in overlapping and concurrent research studies, has said all seven original clinicalRSVP user network sites, including Clinical Pharmacology of Miami, Comprehensive Clinical Development, Elite Research Institute and Seaview Research, have agreed to extend their commitment to the clinicalRSVP network through 2012 and beyond.
In 2009, this group of sites was the first in North America to adopt a subject registry to prevent dual enrollment, increasing data integrity and participant safety for their clients. Since inception, the clinicalRSVP network has grown to include 18 phase I units across the U.S. and Canada, representing more than 20% of the North American phase I beds.
The mission of clinicalRSVP is to provide a single North American registry for investigators to confidentially and securely verify subject eligibility requirements prior to enrollment. clinicalRSVP’s features include controls over electronic records, biometric identification safeguarding, operational ease of use and customer support.
“Ensuring our participants’ safety and facilitating rapid study start-up are the primary focuses for us at Comprehensive Clinical Development,” said Dr. Rae DelVecchio, senior vice president, early phase operations. “We want our sponsors and participants to have total confidence in every aspect of our business and clinicalRSVP is a key component of our enrollment process.”
Darran Boyer, president of clinicalRSVP, said, “We feel this recommitment, as well as our continued growth and proven track record, confirms that clinicalRSVP is the premier network that stops dual enrollment.”